Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
152 hedge funds and large institutions have $1.97B invested in Medicines Co in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 58 increasing their positions, 59 reducing their positions, and 32 closing their positions.
4% more capital invested
Capital invested by funds: $1.9B → $1.97B (+$74.1M)
2% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 59
7% less call options, than puts
Call options by funds: $9.89M | Put options by funds: $10.6M
8% less funds holding
Funds holding: 166 → 152 (-14)
44% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 32
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$56.4M |
| 2 |
BM
Bridger Management
New York
|
+$49.6M |
| 3 |
PC
PointState Capital
New York
|
+$29.2M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$21.7M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$45.8M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$34M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$20.4M |
| 4 |
CCI
Columbus Circle Investors
|
-$15.2M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$14.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Stifel Financial
St. Louis,
Missouri
| – | -$284K | -10,000 | Closed |
|
|
GCP
177
GSA Capital Partners
London,
United Kingdom
| – | -$259K | -9,116 | Closed |
|
|
VKH
178
Virtu KCG Holdings
New York
| – | -$256K | -9,024 | Closed |
|
|
RFC
179
Russell Frank Company
Seattle,
Washington
| – | -$218K | -8,563 | Closed |
|
|
ACI
180
AMP Capital Investors
Sydney,
Australia
| – | -$236K | -8,449 | Closed |
|
181
Neuberger Berman Group
New York
| – | -$238K | -8,390 | Closed |
|
|
TAM
182
Tocqueville Asset Management
New York
| – | -$205K | -7,200 | Closed |
|
|
WMSA
183
Weiss Multi-Strategy Advisers
New York
| – | -$203K | -7,160 | Closed |
|
|
SSG
184
Summit Securities Group
New York
| – | -$85K | -3,000 | Closed |
|
|
TRCT
185
Tower Research Capital (TRC)
New York
| – | -$9K | -319 | Closed |
|
MDCO Hedge Fund Activity: Q2 2014 in Review
152 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2014, worth a combined $1.97B — up 3.9% from $1.9B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of MDCO and 18 opened new positions — a net loss of 14 holders — while 59 trimmed existing stakes and 58 added.
The largest buyer was Putnam Investments, adding an estimated $56.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $45.8M.
- 152 institutional investors held Medicines Co (MDCO) as of Q2 2014, down from 166 in Q1 2014.
- Funds reported $1.97B of Medicines Co stock for Q2 2014, up 3.9% quarter-over-quarter.
- 18 funds opened new Medicines Co positions in Q2 2014 and 32 closed out, a net change of -14 holders.
- The largest Medicines Co buyer in Q2 2014 was Putnam Investments, an estimated $56.4M added.
- The largest Medicines Co seller in Q2 2014 was T. Rowe Price Associates, an estimated $45.8M sold.
Based on aggregated 13F filings for Q2 2014.